Cargando…
Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling
The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752038/ https://www.ncbi.nlm.nih.gov/pubmed/29298347 http://dx.doi.org/10.1371/journal.pone.0190682 |
_version_ | 1783290067528187904 |
---|---|
author | Grundy, Martin Seedhouse, Claire Jones, Thomas Elmi, Liban Hall, Michael Graham, Adam Russell, Nigel Pallis, Monica |
author_facet | Grundy, Martin Seedhouse, Claire Jones, Thomas Elmi, Liban Hall, Michael Graham, Adam Russell, Nigel Pallis, Monica |
author_sort | Grundy, Martin |
collection | PubMed |
description | The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism using the technique of dynamic BH3 profiling, whereby cells were primed with drugs to discover whether this would elicit mitochondrial outer membrane permeabilisation in response to BCL-2-targeting BAD-BH3 peptide or MCL-1-targeting MS1-BH3 peptide. We found that a broad range of anti-leukaemic agents–notably MCL-1 inhibitors, DNA damaging agents and FLT3 inhibitors–sensitise leukaemia cells to BAD-BH3. We further analysed the BCL-2 inhibitors ABT-199 and JQ1, the MCL-1 inhibitors pladienolide B and torin1, the FLT3 inhibitor AC220 and the DNA double-strand break inducer etoposide to correlate priming responses with co-operative induction of apoptosis. ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220. In keeping with the long half-life of BCL-2, the BET domain inhibitor JQ1 was found to downregulate BCL-2 and to prime cells to respond to MS1-BH3 at 48, but not at 4 hours: prolonged priming with JQ1 was then shown to induce rapid cytochrome C release when pladienolide B, torin1, etoposide or AC220 were added. In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1. |
format | Online Article Text |
id | pubmed-5752038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57520382018-01-09 Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling Grundy, Martin Seedhouse, Claire Jones, Thomas Elmi, Liban Hall, Michael Graham, Adam Russell, Nigel Pallis, Monica PLoS One Research Article The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism using the technique of dynamic BH3 profiling, whereby cells were primed with drugs to discover whether this would elicit mitochondrial outer membrane permeabilisation in response to BCL-2-targeting BAD-BH3 peptide or MCL-1-targeting MS1-BH3 peptide. We found that a broad range of anti-leukaemic agents–notably MCL-1 inhibitors, DNA damaging agents and FLT3 inhibitors–sensitise leukaemia cells to BAD-BH3. We further analysed the BCL-2 inhibitors ABT-199 and JQ1, the MCL-1 inhibitors pladienolide B and torin1, the FLT3 inhibitor AC220 and the DNA double-strand break inducer etoposide to correlate priming responses with co-operative induction of apoptosis. ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220. In keeping with the long half-life of BCL-2, the BET domain inhibitor JQ1 was found to downregulate BCL-2 and to prime cells to respond to MS1-BH3 at 48, but not at 4 hours: prolonged priming with JQ1 was then shown to induce rapid cytochrome C release when pladienolide B, torin1, etoposide or AC220 were added. In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1. Public Library of Science 2018-01-03 /pmc/articles/PMC5752038/ /pubmed/29298347 http://dx.doi.org/10.1371/journal.pone.0190682 Text en © 2018 Grundy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Grundy, Martin Seedhouse, Claire Jones, Thomas Elmi, Liban Hall, Michael Graham, Adam Russell, Nigel Pallis, Monica Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
title | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
title_full | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
title_fullStr | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
title_full_unstemmed | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
title_short | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
title_sort | predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic bh3 profiling |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752038/ https://www.ncbi.nlm.nih.gov/pubmed/29298347 http://dx.doi.org/10.1371/journal.pone.0190682 |
work_keys_str_mv | AT grundymartin predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT seedhouseclaire predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT jonesthomas predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT elmiliban predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT hallmichael predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT grahamadam predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT russellnigel predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling AT pallismonica predictingeffectiveproapoptoticantileukaemicdrugcombinationsusingcooperativedynamicbh3profiling |